Evaluation and Management of Microscopic Hematuria in a 40-Year-Old Male
This patient requires urologic evaluation with cystoscopy and upper tract imaging (CT urography preferred), as he meets intermediate-risk criteria based on the 2025 AUA/SUFU guidelines: male age 40 years with 6-8 RBC/HPF hematuria. 1
Risk Stratification
According to the 2025 AUA/SUFU risk stratification system, this patient falls into the intermediate-risk category (0.2%-3.1% malignancy risk) based on:
- Male sex, age 40 years (intermediate-risk threshold is 40-59 years for men)
- 6-8 RBC/HPF (within the 3-10 RBC/HPF range, but age pushes him to intermediate)
- No smoking history (never smoker = low-risk feature, but age overrides this)
The intermediate-risk designation requires full urologic evaluation despite the absence of smoking history and normal renal function 1.
Required Initial Workup
History and Physical Examination Focus
Document these specific elements:
- Detailed family history of kidney disease (assess for hereditary nephritis, polycystic kidney disease, or familial hematuria syndromes)
- Occupational/environmental exposures (aromatic amines, benzene, radiation)
- Irritative voiding symptoms (urgency, frequency, dysuria)
- History of gross hematuria episodes
- Blood pressure measurement (hypertension suggests glomerular disease)
- Medication review (anticoagulants, NSAIDs, cyclophosphamide)
Laboratory Assessment
- Serum creatinine (already normal, but document baseline)
- Urinalysis with microscopy (confirm persistent hematuria on repeat testing)
- Urine protein-to-creatinine ratio or 24-hour protein (proteinuria >300 mg/day suggests glomerular disease)
- Do NOT order urine cytology - it is no longer recommended for routine asymptomatic microscopic hematuria evaluation 1, 2
Urologic Evaluation Protocol
Upper Tract Imaging
Multiphasic CT urography is the preferred imaging modality 2:
- Identifies renal masses, urothelial lesions, stones, and hydronephrosis
- Sensitivity 92%, specificity 93% for upper tract pathology 3
- Superior to ultrasound (sensitivity only 50%) or IVP (sensitivity 38%) 3
Cystoscopy
Mandatory for intermediate-risk patients 1:
- Bladder cancer is the most common malignancy found in hematuria workups
- Cystoscopy is the optimal detection method for bladder lesions
- Delays in bladder cancer diagnosis increase cancer-specific mortality by 34% 1
Nephrologic Considerations
Given the family history of kidney disease, assess for glomerular causes:
- Red blood cell morphology (dysmorphic RBCs suggest glomerular origin)
- Presence of cellular casts (indicates glomerulonephritis)
- Proteinuria (>300 mg/day warrants nephrology referral)
If any of these are present, concurrent nephrology referral is indicated even while proceeding with urologic evaluation 2.
Common Pitfalls to Avoid
Do not attribute hematuria solely to family history of kidney disease without full evaluation - malignancy risk still exists at 0.2%-3.1% 1
Do not delay evaluation waiting for hematuria to resolve - persistent microscopic hematuria requires workup regardless of fluctuations 2
Do not substitute ultrasound for CT urography - ultrasound misses significant upper tract pathology in intermediate-risk patients 3
Do not order voided urine cytology - it adds no value in asymptomatic microscopic hematuria and wastes resources 1, 4
Do not assume normal BUN/creatinine excludes significant pathology - most urologic malignancies and stones occur with normal renal function 3
Follow-Up Strategy
After negative initial evaluation:
- Ongoing surveillance is recommended per guidelines 5
- Repeat urinalysis at 6-12 month intervals
- If hematuria persists or increases in degree, consider repeat evaluation
- If hematuria resolves completely on multiple urinalyses, surveillance intervals can be extended
The family history of kidney disease does not change the urologic evaluation algorithm but should prompt attention to nephrologic causes if proteinuria, hypertension, or renal dysfunction develops during follow-up.